ライフサイエンスコーパス: systemic therapy

1 s; range, 30-88 years; 11 had received prior systemic therapy).

2 with cyclophosphamide and methylprednisolone systemic therapy.

3 umor characteristics and more often received systemic therapy.

4 agnosis, and is increasingly occurring after systemic therapy.

5 ated follicular lymphoma patients in need of systemic therapy.

6 e NSCLC tumors that had been resected before systemic therapy.

7 uable disease, who had not received previous systemic therapy.

8 fore and after the completion of neoadjuvant systemic therapy.

9 1969-2003) and after (2004-2014) advances in systemic therapy.

10 th cGVHD after failure of 1 or more lines of systemic therapy.

11 s when docetaxel + trastuzumab was used as a systemic therapy.

12 mphocytic leukaemia (CLL) who do not require systemic therapy.

13 well owing to the widespread use of adjuvant systemic therapy.

14 hs occurred after 15 years in the absence of systemic therapy.

15 f strategy A over strategy C was the cost of systemic therapy.

16 orubicin administration method, and previous systemic therapy.

17 A) to guide decisions on the use of adjuvant systemic therapy.

18 patients who had undergone previous local or systemic therapy.

19 cinoma have poor prognosis with conventional systemic therapy.

20 were conducted in patients who also received systemic therapy.

21 ancer who are deemed candidates for adjuvant systemic therapy.

22 ntial whole-breast irradiation, and adjuvant systemic therapy.

23 n who did not receive the indicated adjuvant systemic therapy.

24 r guiding decisions on the need for adjuvant systemic therapy.

25 with breast-conserving therapy and adjuvant systemic therapy.

26 safely undergo surveillance before starting systemic therapy.

27 phy was predominantly the result of improved systemic therapy.

28 ssive mCRPC immediately prior to new line of systemic therapy.

29 e fluocinolone acetonide implant or standard systemic therapy.

30 outcome in patients with advanced HCC before systemic therapy.

31 influence the timing of surgery relative to systemic therapy.

32 itivity within weeks following initiation of systemic therapy.

33 fore and after the completion of neoadjuvant systemic therapy.

34 lay (sometimes indefinitely) the delivery of systemic therapy.

35 rmatory diagnostic testing before initiating systemic therapy.

36 er during or at the completion of first-line systemic therapy.

37 search was restricted to articles evaluating systemic therapy.

38 long plasma circulation, which is useful for systemic therapy.

39 as patients with multisystem disease require systemic therapy.

40 normally treated with palliative intent and systemic therapy.

41 llular carcinoma not previously treated with systemic therapy.

42 Surgery is standard with no approved systemic therapy.

43 SCLC) that did not progress after front-line systemic therapy.

44 in guiding decisions on the use of adjuvant systemic therapy.

45 n could serve as a base for future trials of systemic therapy.

46 sis, and were candidates for phototherapy or systemic therapy.

47 man disease and emphasizes the importance of systemic therapy.

48 emonstrated higher response rates than other systemic therapies.

49 vival, particularly in patients treated with systemic therapies.

50 o GVHD treatment, and 14 of 17 required >/=2 systemic therapies.

51 onsible for the poor response of patients to systemic therapies.

52 noma carries a poor prognosis despite modern systemic therapies.

53 uncover biomarkers predictive of response to systemic therapies.

54 ct, on the basis of incidence and benefit of systemic therapies.

55 ration can decrease the benefit of cytotoxic systemic therapies.

56 n overall survival (OS) of 12-14 months with systemic therapies.

57 ts were enrolled, with a median of two prior systemic therapies.

58 emonstrated higher response rates than other systemic therapies.

59 ntifies predictive biomarkers of response to systemic therapies.

60 and off-target side effects associated with systemic therapies.

61 avily pretreated with a median of four prior systemic therapies.

62 ent discontinuation, even without subsequent systemic therapies.

63 generally incurable, due to a lack of active systemic therapies.

64 lder, and had received at least two previous systemic therapies.

65 icular lymphoma (FL) after two or more prior systemic therapies.

66 riginal treatment plan included avoidance of systemic therapy (17%-40%) and PET-directed local therap

67 between the 2 treatment groups (implant vs. systemic therapy, 2 letters; 95% CI, -10 to 15 letters;

68 ed by treatment sequence: (1) surgery before systemic therapy, (2) systemic therapy before surgery, a

69 teen patients were using a self-administered systemic therapy; 22.4% were classified as "non-adherent

70 visual acuity from baseline (implant, 61.7; systemic therapy, 65.0) through 7 years (implant, 55.8;

71 erapy, 65.0) through 7 years (implant, 55.8; systemic therapy, 66.2) favored systemic therapy by 7.2

72 oregional disease (126/382, 33%), and toward systemic therapy (69% M1a; 43% M1b/c) for metastatic dis

73 uveitic eyes (71% of 90 patients assigned to systemic therapy) (77% female; median age at enrollment,

74 s substantially higher risk of glaucoma than systemic therapy, a difference not entirely explained by

75 reviously developed to assess the quality of systemic therapy across four domains (access, treatment

76 As systemic therapy advances provide better control of dist

77 ies and investigate the benefits of adjuvant systemic therapies after curative resection/ablation.

78 is interest in the use of AC, the benefit of systemic therapy after neoadjuvant chemoradiation and es

79 assigned (1:1) to receive standard adjuvant systemic therapy alone (control group) or with zoledroni

80 Among 24,015 women, 56.2% (13,505) underwent systemic therapy alone and 43.8% (10,510) underwent surg

81 Notwithstanding, the use of systemic therapy alone can result in a castrate-resistan

82 wed by adjuvant systemic therapy relative to systemic therapy alone for patients with breast cancer l

83 st-effectiveness of strategy B (conventional systemic therapy alone).

84 oved to be cost-effective when compared with systemic therapy alone, particularly in estrogen recepto

85 d adjusted overall survival when compared to systemic therapy alone.

86 y may have greater therapeutic efficacy than systemic therapy alone.

87 vitreal foscarnet may be more effective than systemic therapy alone.

88 (2) systemic therapy before surgery, and (3) systemic therapy alone.

89 metastatic disease lesions after first-line systemic therapy, an Eastern Cooperative Oncology Group

90 ymal stromal cell therapy as alternatives to systemic therapies and antibiotics for patients with inf

91 Systemic therapies and radiotherapy boost did not increa

92 tunities for improving patient selection for systemic therapies and, ultimately, patient outcomes.

93 carriage, all of whom had received antenatal systemic therapy and 2 during the first trimester.

94 e base covered questions related to adjuvant systemic therapy and included a systematic review conduc

95 led, all with liver metastases refractory to systemic therapy and ineligible for surgical resection.

96 ith standard-of-care adjuvant or neoadjuvant systemic therapy and locoregional treatments would incre

97 ravitreous fluocinolone acetonide implant vs systemic therapy and long-term visual and other outcomes

98 nd stratified according to duration of prior systemic therapy and presence of liver metastases.

99 portantly, therapeutic advances in multidrug systemic therapy and radiation therapy have already been

100 ults with metastatic brain tumors, including systemic therapy and supportive care topics.

101 m, stratified by number of previous lines of systemic therapy and the presence of liver metastases, t

102 hallenging; (2) Patients can tolerate modern systemic therapy and undergo successful surgical resecti

103 g a treatment-free interval or during active systemic therapy and whether or not an oligometastatic l

104 orbidity, the introduction of new, effective systemic therapies, and the improvement in survival time

105 2 or less, had received standard first-line systemic therapy, and had no disease progression before

106 o or experienced progression on >= 1 line of systemic therapy, and other advanced malignancies.

107 regional (surgery and radiation therapy) and systemic therapy approaches.

108 C), and predictive biomarkers of response to systemic therapies are lacking.

109 ed with surgery and radiotherapy, as current systemic therapies are largely ineffective.

110 Skin-directed and systemic therapies are used as monotherapy or in combina

111 s after brain radiotherapy and HER2-targeted systemic therapy are a difficult therapeutic challenge.

112 strategies of locoregional therapies and/or systemic therapy are being investigated.

113 essed (P < 0.016), although most eyes in the systemic therapy arm also showed substantial improvement

114 l resection of the primary tumor followed by systemic therapy (Arm A) or primary systemic therapy (Ar

115 lowed by systemic therapy (Arm A) or primary systemic therapy (Arm B) in Austria.

116 ients with autoimmune diseases that required systemic therapy at screening were excluded from the stu

117 by assigned treatment (129 implants vs. 126 systemic therapies) because of substantial differences i

118 Treatment with systemic therapy before surgery was associated with larg

119 ce: (1) surgery before systemic therapy, (2) systemic therapy before surgery, and (3) systemic therap

120 to Alliance for Clinical Trials in Oncology systemic therapy breast cancer trials during 1985-2012 a

121 ups held strong beliefs about their need for systemic therapy but differed in levels of medication co

122 plant, 55.8; systemic therapy, 66.2) favored systemic therapy by 7.2 (95% CI, 2.1-12) letters.

123 ducing the clinical toxicity associated with systemic therapy by concentrating the immunomodulatory p

124 % (17/209) of eyes assigned and treated with systemic therapy (censoring eyes receiving an implant on

125 Receipt of systemic therapy combinations including trastuzumab was

126 ease following one or more previous lines of systemic therapy consisting of at least two cycles of a

127 rior, or panuveitis randomized to implant or systemic therapy (corticosteroid plus immunosuppression

128 ere treated with 1 or more of the following: systemic therapy (corticosteroids or other immunosuppres

129 ed FU plus LV with a potentially more active systemic therapy could further improve overall survival.

130 Demographic, surgical, pathological, and systemic therapy data were captured with uniform databas

131 entially modifiable by alteration in initial systemic therapy decisions.This is an open access articl

132 he first prospective trial evaluating modern systemic therapy delivered in a neoadjuvant/perioperativ

133 acting OS, whereas discrepancies in adjuvant systemic therapies did not impact LR, DM, or OS of leiom

134 linicians when choosing between non-biologic systemic therapies, etanercept, adalimumab, and ustekinu

135 ing ocular melanoma), and up to one previous systemic therapy (excluding anti-CTLA-4, PD-1, or PD-L1

136 is common and no other effective classes of systemic therapy exist.

137 nd/or metastatic disease, no known effective systemic therapy exists.

138 n, downstaging preoperative radiotherapy and systemic therapy, extensive surgery for locoregional and

139 postoperative radiotherapy with and without systemic therapy following primary surgery of OPSCC, ind

140 system and stratified by number of previous systemic therapies for advanced breast cancer and measur

141 No specific systemic therapies for advanced disease can be recommend

142 estimate the relative efficacy and safety of systemic therapies for advanced, treatment-naive, BRAF-m

143 Advances in systemic therapies for breast cancer have not substantiv

144 Available systemic therapies for CTCL may variably decrease tumor

145 Despite the success of approved systemic therapies for estrogen receptor alpha (ER)-posi

146 Systemic therapies for inflammatory bowel disease are as

147 ans of predicting canine OMM metastasis, and systemic therapies for metastatic disease are largely pa

148 could provide the basis for promising novel systemic therapies for MFS and UPS.

149 Use of systemic therapies for moderate to severe psoriasis in c

150 Effective systemic therapies for patients with advanced, progressi

151 f patient relapse and to monitor efficacy of systemic therapies for personalised cancer patient manag

152 inforcing the need to develop and administer systemic therapies for this neuromuscular disease.

153 on-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0

154 Patients who had not received systemic therapy for advanced anal cancer were randomly

155 breast cancer who had not received previous systemic therapy for advanced disease.

156 randomized controlled trials (2007-2020) on systemic therapy for advanced HCC and provide recommende

157 osine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (

158 Purpose Systemic Therapy for Advanced or Metastatic Prostate Can

159 Randomized clinical trials of neoadjuvant systemic therapy for breast cancer may help resolve this

160 ans and patients is appropriate for adjuvant systemic therapy for breast cancer.

161 ay reduce the efficacy of molecularly guided systemic therapy for cancers that have metastasized.

162 Most patients had received prior systemic therapy for metastatic disease (cervical, 78.9%

163 Systemic therapy for metastatic melanoma has evolved rap

164 Systemic therapy for metastatic non-small cell lung canc

165 continued on observation until initiation of systemic therapy for metastatic renal-cell carcinoma; a

166 lacebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma.

167 Systemic therapy for nonmetastatic breast cancer is dete

168 n radical local therapy is added to standard systemic therapy for oligometastatic disease.

169 These data may guide selective use of systemic therapy for patients with round cell and pleomo

170 ndations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non-small-ce

171 ndations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-ce

172 half of patients with sarcoidosis will need systemic therapy for their disease.

173 Twenty patients received systemic therapy for widely disseminated disease.

174 set priorities for improving the quality of systemic therapy for women with early-stage breast cance

175 l therapy and matched controls not receiving systemic therapy from April 11, 2011, through June 30, 2

176 Systemic therapy given for lymphoma after the first trim

177 mulative 7-year incidence in the implant and systemic therapy groups, respectively, was less than 10%

178 , or panuveitis, those randomized to receive systemic therapy had better visual acuity than those ran

179 ad relapsed or was refractory to two or more systemic therapies, had an Eastern Cooperative Oncology

180 or 1, had received no more than two previous systemic therapies, had measurable disease according to

181 However, no systemic therapy has gained regulatory approval for the

182 The landscape of systemic therapy has recently changed, with six addition

183 ous cell carcinoma is a deadly disease where systemic therapy has relied upon empiric chemotherapy de

184 ents develop distant metastases, but current systemic therapies have limited efficacy.

185 es in locoregional therapies, radiation, and systemic therapies have provided better therapeutic opti

186 Whether advances in systemic therapies have rendered previously observed ben

187 Receipt of surgery, whether before or after systemic therapy (Hazard Ratio, 0.68; 95% confidence int

188 on score, Estrogen Receptor status, adjuvant systemic therapy, histology, and tumor size.

189 hospitalization than with use of nonbiologic systemic therapies; however, further investigation is wa

190 (HR, 1.002; 95%CI, 1.0004-1.003), subsequent systemic therapy (HR, 0.04; 95%CI, 0.006-0.24), and live

191 As systemic therapies improve, patients with lung cancer li

192 om NSCLC that did not progress after initial systemic therapy improved progression-free survival comp

193 parison with a cohort receiving non-biologic systemic therapies in a propensity score-weighted Cox pr

194 e published studies included a wide range of systemic therapies in cutaneous and noncutaneous melanom

195 efficacy exceeding those of other third-line systemic therapies in mCRPC patients.

196 entified all randomised controlled trials of systemic therapies in non-small-cell lung cancer, breast

197 andomized clinical trials (RCTs) of adjuvant systemic therapy in breast cancer make them impractical

198 gery followed by systemic therapy to primary systemic therapy in de novo stage IV breast cancer.

199 maPrint assay to guide decisions on adjuvant systemic therapy in patients with hormone receptor-posit

200 ed to characterise the time to initiation of systemic therapy in patients with metastatic renal-cell

201 enefit of hepatic radioembolization added to systemic therapy in the first- and second-line treatment

202 point of the study was time to initiation of systemic therapy in the per-protocol population.

203 The use of neoadjuvant systemic therapy in the treatment of breast cancer patie

204 nation, and volume regimens with and without systemic therapy in the treatment of OPSCC are outlined

205 Systemic therapies include endocrine therapy for hormone

206 who subsequently progressed and had further systemic therapies, including (177)Lu-PSMA.

207 The introduction of systemic therapies, including immune-based therapies and

208 who subsequently progressed and had further systemic therapies, including LuPSMA.

209 cellular carcinoma with one or more previous systemic therapies, including sorafenib, were randomly a

210 col therapy cessation and time to subsequent systemic therapy initiation or death.

211 The pipeline of more targeted topical and systemic therapies is expanding based on our growing und

212 reast cancer, escalation or de-escalation of systemic therapy is a controversial topic.

213 r metabolic activity after the initiation of systemic therapy is an indicator of active disease, wher

214 recurrent malignancy at 1 year after initial systemic therapy is associated with clinical benefit, a

215 Increasingly, some systemic therapy is delivered before surgery.

216 d during transfection) have been used when a systemic therapy is indicated for large tumour burden an

217 ent disease or distant spread, in which case systemic therapy is used to control disease and palliate

218 NSCLC that did not progress after front-line systemic therapy, LCT prolonged PFS and OS relative to M

219 ry, or who received preoperative/neoadjuvant systemic therapy may be offered SNB.

220 Targeted systemic therapy may be used to treat advanced or metast

221 estrogen-receptor status, type and timing of systemic therapy, menopausal status, statin use, and tre

222 dations; six randomized controlled trials of systemic therapy met eligibility criteria.

223 Despite emergence of new systemic therapies, metastatic melanoma remains a challe

224 Systemic therapies must be considered carefully in light

225 ing metastatic disease (M1) before or during systemic therapy (n = 70/388, 18%) between September 201

226 Alternative systemic therapies need to be assessed in combination wi

227 (ypN0) in patients treated with neoadjuvant systemic therapy (NST) for different breast cancer subty

228 Optimal axillary staging after neoadjuvant systemic therapy (NST) in node-positive breast cancer is

229 assessment of tumor response to neoadjuvant systemic therapy (NST) in patients with breast cancer an

230 cancer (BC) patients undergoing neoadjuvant systemic therapy (NST); however, clinical evidence is li

231 od-based biomarkers, functional imaging, and systemic therapy of advanced NETs and discuss results of

232 oaches and evolving strategies for local and systemic therapy of breast cancer.

233 terminated the pregnancy to allow immediate systemic therapy; of the remaining 36 women, 24 received

234 Four of 21 patients (19%) receiving other systemic therapies on progression experienced a PSA decl

235 rature and discuss the potential second-line systemic therapy options for advanced biliary tract canc

236 of successful randomized trials provides new systemic therapy options for patients with metastatic so

237 s poor overall survival (OS) and no approved systemic therapy options.

238 % CI = 0.60-1.41) compared with non-biologic systemic therapies or methotrexate-only (etanercept: HR

239 value particularly in patients treated with systemic therapy (P < 0.01), whereas the prognostic valu

240 mainly observed in patients not treated with systemic therapy (P < 0.01).

241 idisciplinary, involving surgery, radiation, systemic therapies, pathology, radiology, and other spec

242 ned progression-free survival from the first systemic therapy (PFS) until progression on the second s

243 herapy (PFS) until progression on the second systemic therapy (PFS2) was also explored.

244 o experienced progression after at least one systemic therapy (phase Ib) or were treatment naive (pha

245 Present systemic therapies rarely provide reliable and durable r

246 A systematic review of systemic therapy RCTs in STS was performed.

247 After 2 years of tamoxifen vs no systemic therapy, regardless of hormone receptor status,

248 experienced disease progression after prior systemic therapy, regardless of tumor MSI status.

249 ness of liver resection followed by adjuvant systemic therapy relative to systemic therapy alone for

250 could provide the basis for promising novel systemic therapies.See related commentary by Lambert and

251 We suggest that neoadjuvant systemic therapy should be considered as the new standar

252 ommendations for confirmatory testing before systemic therapy should be reconsidered and replaced wit

253 axillary nodal involvement after neoadjuvant systemic therapy should receive PMRT.

254 The explosion in systemic therapies since then has resulted in significan

255 e of the toxicity and non-curative nature of systemic therapy, some of these patients could benefit f

256 re elevated among patients with PsO (without systemic therapy [ST] 1.37; with ST 1.97), PsA (without

257 ction followed by postoperative conventional systemic therapy (strategy A) versus conventional therap

258 n the context of treatment with contemporary systemic therapies such as immunotherapies and targeted

259 atment included a combination of topical and systemic therapies, such as corticosteroids, dapsone, is

260 tic) and for different treatment modalities (systemic therapy, surgery, radiation therapy).

261 great potential for clinical translation of systemic therapies targeting neuroinflammation and brain

262 olation in individuals receiving nonbiologic systemic therapy than in those receiving biologics (OR =

263 more frequent in patients using nonbiologic systemic therapy than in those using biologics (OR = 2.8

264 al therapy inherently attractive compared to systemic therapy that exposes the whole body to a drug.

265 ndations Recommendations for the addition of systemic therapy to definitive radiotherapy in the treat

266 a manner that prioritizes early exposure to systemic therapy to maximize the treatment of micrometas

267 rvival comparing primary surgery followed by systemic therapy to primary systemic therapy in de novo

268 -cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at

269 Pexidartinib is the first systemic therapy to show a robust tumour response in TGC

270 with breast-conserving surgery and adjuvant systemic therapy to undergo either whole-breast irradiat

271 rative treatment sequencing, and response to systemic therapy, to safely guide patients through this

272 influence surgical decisions and may affect systemic therapy trial eligibility, all young women with

273 previous treatment with at least one line of systemic therapy (unless no standard treatment existed o

274 4 of 21 patients (19%) receiving other systemic therapies upon progression experienced PSA decl

275 d non-adherence to conventional and biologic systemic therapies used for psoriasis and evaluated psyc

276 clude locoregional therapies, radiation, and systemic therapy used alone or in combination with other

277 identify predictors of primary resistance to systemic therapies using circulating tumor DNA (ctDNA).

278 Single-dose systemic therapy (usually injectable ceftriaxone plus or

279 Median number of prior systemic therapies was 2 (range, 1-9), and 63% received

280 om registration on study until initiation of systemic therapy was 14.9 months (95% CI 10.6-25.0).

281 mean interval between diagnosis and starting systemic therapy was 3.0 years.

282 patients in 25 randomized trials of adjuvant systemic therapy was conducted.

283 on, which despite clinical improvement under systemic therapy was only partially reverted, and which

284 omatic patients with CLL who did not require systemic therapy were enrolled at MD Anderson Cancer Cen

285 ed > 6 months before study entry and 1 prior systemic therapy were randomly assigned (1:1) to ganetes

286 own BRAF(V600) status and up to one previous systemic therapy were randomly assigned (1:1:1) to intra

287 tive breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in Sou

288 d with strategy B when letrozole was used as systemic therapy, whereas it was only 0.3 QALMs when doc

289 However, unlike conventional systemic therapies, which are directly cytotoxic to tumo

290 espite multimodal treatments and advances in systemic therapies, which include a combination of surge

291 C, following a prolonged period of induction systemic therapy, will be an area of intense scrutiny.

292 disease, as well as integration of effective systemic therapies with localised interventions, might a

293 Thus, systemic therapy with activated MSC may be an effective

294 Three patients underwent systemic therapy with diminution of the deposits and imp

295 He began systemic therapy with ipilimumab and nivolumab.

296 ed comparative effectiveness trial comparing systemic therapy with oral corticosteroids and immunosup

297 ments, including sentinel lymph node biopsy, systemic therapy with taxanes, platinum agents, or dose-

298 d progressed after no more than one previous systemic therapy, with an Eastern Cooperative Oncology G

299 randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up.

300 ans for treatment (surgery, radiotherapy, or systemic therapy) within 90 d for lung and 180 d for pro